US20090123442A1 - Expanded nk cells - Google Patents
Expanded nk cells Download PDFInfo
- Publication number
- US20090123442A1 US20090123442A1 US11/938,123 US93812307A US2009123442A1 US 20090123442 A1 US20090123442 A1 US 20090123442A1 US 93812307 A US93812307 A US 93812307A US 2009123442 A1 US2009123442 A1 US 2009123442A1
- Authority
- US
- United States
- Prior art keywords
- cells
- patient
- expanded
- tumors
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 188
- 210000004027 cell Anatomy 0.000 claims abstract description 151
- 230000003013 cytotoxicity Effects 0.000 claims abstract description 34
- 231100000135 cytotoxicity Toxicity 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 34
- 230000001472 cytotoxic effect Effects 0.000 claims abstract description 30
- 231100000433 cytotoxic Toxicity 0.000 claims abstract description 25
- 230000003211 malignant effect Effects 0.000 claims abstract description 25
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 58
- 102000005962 receptors Human genes 0.000 claims description 51
- 108020003175 receptors Proteins 0.000 claims description 51
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 230000003213 activating effect Effects 0.000 claims description 30
- 210000004881 tumor cell Anatomy 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 18
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 18
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 15
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 15
- 238000011476 stem cell transplantation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 102100038077 CD226 antigen Human genes 0.000 claims description 11
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 10
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 10
- 230000000735 allogeneic effect Effects 0.000 claims description 10
- 208000034578 Multiple myelomas Diseases 0.000 claims description 9
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 7
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 7
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 7
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 7
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 7
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 238000009109 curative therapy Methods 0.000 claims description 3
- 230000002489 hematologic effect Effects 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 17
- 201000000050 myeloid neoplasm Diseases 0.000 description 49
- 239000012636 effector Substances 0.000 description 16
- 238000000684 flow cytometry Methods 0.000 description 16
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
- 210000001185 bone marrow Anatomy 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000003827 upregulation Effects 0.000 description 10
- 102100027207 CD27 antigen Human genes 0.000 description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 108091008042 inhibitory receptors Proteins 0.000 description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 7
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 238000002784 cytotoxicity assay Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000036210 malignancy Effects 0.000 description 6
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 4
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 4
- 108010043610 KIR Receptors Proteins 0.000 description 4
- 102000002698 KIR Receptors Human genes 0.000 description 4
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 4
- 102100035721 Syndecan-1 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 3
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 3
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 3
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 description 3
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 description 3
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 101150069255 KLRC1 gene Proteins 0.000 description 3
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 3
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 3
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 description 3
- -1 Lir-1 Proteins 0.000 description 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 3
- 239000012979 RPMI medium Substances 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 2
- 102100022339 Integrin alpha-L Human genes 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 108010017736 Leukocyte Immunoglobulin-like Receptor B1 Proteins 0.000 description 2
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 102000027581 NK cell receptors Human genes 0.000 description 2
- 108091008877 NK cell receptors Proteins 0.000 description 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940124622 immune-modulator drug Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 101100485276 Arabidopsis thaliana XPO1 gene Proteins 0.000 description 1
- 102100021661 Aryl hydrocarbon receptor nuclear translocator-like protein 2 Human genes 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000896221 Homo sapiens Aryl hydrocarbon receptor nuclear translocator-like protein 2 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 description 1
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 description 1
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101100407739 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PET18 gene Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003112 degranulating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
Definitions
- the present invention relates to expanded natural killer (NK) cells being cytotoxic against malignant cells and a method of treatment of malignant disease.
- NK natural killer
- NK cells are cytotoxic lymphocytes that lyse certain tumor and virus infected cells without any prior stimulation or immunization. NK cells are also potent producers of various cytokines, e.g. IFN- ⁇ , TNF- ⁇ , GM-CSF and IL-3. Therefore, NK cells are also believed to function as regulatory cells in the immune system, influencing other cells and responses.
- cytokines e.g. IFN- ⁇ , TNF- ⁇ , GM-CSF and IL-3. Therefore, NK cells are also believed to function as regulatory cells in the immune system, influencing other cells and responses.
- NK cells are broadly defined as CD56 + CD3 ⁇ lymphocytes.
- the cytotoxic activity of NK cells is tightly controlled by a balance between the activating and inhibitory signals from receptors on the cell surface.
- a main group of receptors that inhibits NK cell activation are the inhibitory killer immunoglobulin-like receptors (KIRs).
- KIRs inhibitory killer immunoglobulin-like receptors
- Activating receptors include the natural cytotoxicity receptors (NCR) and NKG2D that push the balance towards cytolytic action through engagement with different ligands on the target cell surface.
- Cytokines are used in the treatment of some human cancers and NK cell differentiation and activation is affected by cytokines such as interleukins (e.g. IL-2, IL-12. IL-15, IL-18 and IL-21).
- cytokines such as interleukins (e.g. IL-2, IL-12. IL-15, IL-18 and IL-21).
- the effect of IL-2 administration on activation and expansion of NK cells in cancer patients have been assessed in several trials with mixed outcomes depending on type of tumor and the conditions used for IL-2 administration.
- One example of cellular therapy is the NK cell-mediated killing of leukaemia cells which is based on NK cell alloreactivity.
- MM Multiple myeloma
- BM bone marrow
- the malignant cells are associated with the synthesis of monoclonal immunoglobulin and a high incidence of osteolytic bone lesions.
- the disease accounts for about 2% of all cancer deaths and nearly 20% of deaths caused by hematological malignancies.
- allogeneic stem cell transplantation occasionally cures these patients and drugs like thalidomide, lenalidomide and bortezomib have improved outcome, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) still appears to be the best treatment for patients up to 65-70 years of age.
- ASCT autologous stem cell transplantation
- NK cells In order to use NK cells in adoptive immunotherapeutic strategies, the availability of functionally active NK cells on a clinical scale is crucial. Clinical trials that have been performed using autologous NK cells were hampered by the fact that the cell dose was inadaptable to the demands of clinical trials. Therefore, the development of protocols for large-scale generation of NK cells is important to evaluate the potential of NK cell-based therapeutic protocols. Examples of reports that deal with ways of expanding and culturing human NK-cells are U.S. Ser. No. 10/242,788 and WO 2006/052534.
- Human ex vivo expanded NK cells would be favorable candidates for immunotherapeutic approaches against malignant disease if they could target tumor cells.
- One aim of the invention is to provide expanded and active CD56 + CD3 ⁇ NK cells.
- Another aim of the invention is to provide expanded CD56 + CD3 ⁇ NK cells that are cytotoxic against cells of malignant disease.
- Yet another aim is to provide a method of treatment of a malignant disease.
- the present invention relates to ex vivo expanded natural killer (NK cells) that can be used for immunotherapy of tumor cells, the NK cells showing no significant cytotoxicity against normal cells.
- the NK cells according to the invention are ex vivo expanded and active cells having the phenotype CD56 + CD3 ⁇ . This phenotype is specifically toxic against tumor cells. Upregulation of at least one activating receptor contributes to the cytotoxic activity of the expanded NK cells.
- the invention relates to a composition comprising the NK cells according to the invention.
- the present invention relates to a method of treatment of a malignant disease wherein NK cells according to the invention or a composition according to the invention are/is administered to a patient with a malignant disease, or a patient undergoing autologous stem cell transplantation for cancer, or a patient with a malignant disease following allogeneic stem cell transplantation, or a patient with haematological malignancies, or a patient with solid tumors, in a pharmaceutically effective dose.
- the term “about” is used to indicate a deviation of +/ ⁇ 2% of the given value, preferably +/ ⁇ 5%, and most preferably +/ ⁇ 10% of the numeric values, where applicable.
- NK natural killer
- activating NK cells refers to NK cells that have received an activating signal, thus being capable of killing cells with deficiencies in MHC class I expression.
- NK cell expansion relates to the culturing of NK cells that go through a series of cell division and thus expand in number of cells present in the culture.
- the term “expanded NK cells” relates to NK cells obtained through NK cell expansion. More specifically, in one embodiment the term “expanded NK cells” relates to a polyclonal group of chronically activated CD56 + CD3 ⁇ cells, expanded in a specific cGMP grade environment and cGMP grade medium.
- the term “upregulation of receptor” relates to the increase in receptor density per cell.
- cells that have a “cytotoxic phenotype” relates to cells that are toxic, i.e. they induce the death of other cells such as, but not limited to, tumor cells, infected cells or cells that are otherwise damaged or dysfunctional.
- Cytotoxic cells of the present invention are mainly toxic to tumor cells.
- the cytotoxicity of NK cells towards other cells can easily be measured, for example, by traditional cell counting before and after exposure to the NK cells according to the invention.
- suitable methods are, but not limited to, fluorescent cell counting assay, immunofluorescent cell counting assay, cell viability assay, and flow cytometry-based cytotoxicity assay.
- effector cell relates to a cell that performs a specific function in response to a stimulus such as cells in the immune system.
- effector cells are a type of lymphocytes that are actively engaged in secreting antibodies.
- Non-limiting examples of effector cells are NK cells, T cells and NK-like T cells
- NK natural killer
- Ex vivo expansion and reinfusion of natural killer (NK) cells to patients afflicted with a malignant disease offers a new potentially interesting therapeutic approach to combat such a disease.
- a prerequisite for this is the possibility to expand and use NK cells that meet the demands of clinical trials.
- the present inventors have surprisingly shown that ex vivo expanded NK cells can be used for immunotherapy of tumor cells that often express varying levels of MHC class I molecules, the NK cells showing no significant cytotoxicity against normal cells.
- the present invention relates to ex vivo expanded and activated natural killer cells having the phenotype CD56 + CD3 ⁇ .
- the NK cells according to the invention are expanded, active and have a phenotype cytotoxic against tumor cells, preferably autologous tumor cells.
- the NK cells can be obtained from any conventional source and are preferably derived from peripheral blood, bone marrow, cord blood, cell lines or cytokine stimulated peripheral blood.
- NK cells can, for example; be expanded from a sample of peripheral blood mononuclear cells (PBMCs).
- PBMCs are a mixture of monocytes and lymphocytes; blood leucocytes from which granulocytes have been separated and removed.
- the culture conditions are outlined below in “Experimentals”.
- the NK cells should be expanded for at least about 5 days, preferably not less than about 10 days, more preferably not less than about 15 days and most preferably not less than about 20 days. Already after 5 days the NK cells can show anti-tumor activity.
- the NK cells according to the invention should be expanded at least about 100 fold, preferably at least about 200 fold, more preferably at least about 400 fold, more preferably at least about 600 fold, more preferably at least about 1000 fold and even more preferably at least about 1500 fold.
- the activating pathway of NK cells also includes a series of different receptors. Activating receptors do not directly signal through their cytoplasmic tail, but instead associate non-covalently with other molecules containing ITAMs (immunoreceptor tyrosine-based activation motifs), that serve as the signal transducing proteins. Thus, according to one embodiment of the invention the ex vivo expanded and activated NK cells have an upregulated expression of at least one activating receptor.
- activating receptors are: CD16 (Fc ⁇ RIII), CD25 (IL-2R ⁇ ), CD27, CD28, CD69, CD94, CD122 (IL-2R ⁇ ), CD161, CD226 (DNAM-1), 2B4 (CD244), CD314 (NKG2D), KIR2S, KIR3S, NCRs (natural cytotoxicity receptors) such as NKp30, NKp44, and NKp46, CD85H (ILT-1) and IFN- ⁇ / ⁇ R.
- said at least one activating receptor is selected from the group consisting of 2B4, CD8, CD16, CD 27, CD226, NKG2D, NKp30, NKp44 and NKp46.
- the at least one activating receptor is 2B4 or CD226.
- the NK cells according to the present invention exhibit higher degranulation activity compared to non-expanded NK cells.
- the degranulation activity can be estimated through the determination of the CD107a expression.
- CD107a surface expression correlates closely with degranulation and release of cytotoxic granules.
- Degranulation as measured by CD107a expression correlates to cytotoxic activity of an effector cell, such as an NK cell.
- the method of determining degranulation activity through the determination of CD107a expression is well known to a person skilled in the art. See, for example, Alter G, Malieri J M, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294:15-22.
- the change in receptor expression can be calculated by mean fluorescence intensity (MFI) ratios:
- x is the number of days of expansion of the NK cell.
- MFI ratio When the MFI for day X samples is higher than for day 0, the MFI ratio will be higher than 1, which indicates the relative extent of upregulation in that receptor. Thus, a MFI ratio of e.g. 1.5 would mean a 50% of upregulation of a specific receptor. The calculation of MFI ratios is well known to persons skilled in the art.
- the at least one activating receptor is upregulated by at least about 50%, preferably at least about 75, more preferably at least about 100% and most preferably at least about 200%.
- the NK cells have a down-regulated expression of at least one receptor, such as an inhibitory receptor or a chemokine receptor (e.g. CCR7).
- inhibiting receptors are inhibitory killer immunoglobulin-like receptors (KIRs).
- KIRs inhibitory killer immunoglobulin-like receptors
- GL183, KIR2DL1, Lir-1, NKB1, and NKG2A inhibitory killer immunoglobulin-like receptors
- the NK cells according to the invention can have an upregulated expression of at least one activating receptor and a down-regulated expression of at lest one receptor.
- the NK cells according to the invention can have an upregulated expression of at least one activating receptor and a downregulated expression of at lest one inhibitory receptor.
- the expanded and activated NK cells have at least about 100% increased cytotoxicity compared to non-ex vivo expanded NK cells. Preferably at least about 150%, more preferably at least about 200% and most preferably at least about 400% increased cytotoxicity compared to non-expanded NK cells.
- Non expanded NK cells relates to freshly isolated NK cells and short-term activated NK cells.
- short term activated means NK cells that have been expanded over night only.
- the increased cytotoxicity of the expanded and activated NK cells can also be an effect mediated by an upregulation of a combination of receptors.
- the present invention relates to expanded and activated NK cells having an upregulated expression of more than one receptor.
- recognition of the target cell by NK cells can involve a combination of receptors that synergistically deliver activating signals.
- compositions comprising the expanded and active NK cells as described above.
- a composition according to the invention may also contain any suitable physiological buffer, such as, but not limited to, phosphate buffered saline. Suitable physiological buffers are well known to the skilled person.
- Other substances such as, but not limited to cytokines such as IL-2 and its derivatives, immunomodulatory drugs and proteosome inhibitors, that increase the effect of the administered cells can also be added to the composition or administered separately.
- the composition also contains lower levels of other cells.
- Non-expanded PBMCs usually contain a mixture of different cells, for example, NK cells (CD56 + CD3 ⁇ ), NK-like T cells (CD56 + CD3 + ) and T cells (CD56 ⁇ CD3 + ).
- NK cells CD56 + CD3 ⁇
- NK-like T cells CD56 + CD3 +
- T cells CD56 ⁇ CD3 +
- NK cells according to the invention can also be administered or used in combination with other cancer therapies, such as, but not limited to, surgery, radiation and cytotoxic drugs.
- NK cells can eliminate cancer cells.
- the results of the study underlying the present invention suggest that ex vivo expanded and activated cells have a promising anti-tumor potential compared to resting NK cells.
- the present invention also relates to NK cells being cytotoxic against tumor cells, said tumor cells preferably being autologous tumor cells.
- Autologous tumor cells refer to cells that are reimplated in the same individual as they came from, i.e. the donor and the recipient are the same person.
- Allogeneic tumor cells refers to cells taken from different individuals of the same species, i.e. genetically non-identical individuals. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical.
- the NK cells according to the present invention are cytotoxic against tumor cells, said tumor cells being selected from, but not limited to, the group consisting of haematological tumors or malignancies and solid tumors or malignancies.
- Haematological tumors or malignancies include types of cancer that affects the blood, the bone marrow and the lymph nodes.
- the NK cell according to the invention is cytotoxic against cells of lymphoma (e.g. Hodgkin's disease and non-Hodgkin's lymphoma), multiple myeloma (MM), and leukaemia (e.g.
- NK cells are cytotoxic against multiple myeloma cells.
- the present invention also relates to a method of treatment.
- autologous ex vivo expanded and activated NK cells might be helpful for treatment of minimal residual disease (MRD) after autologous stem cell transplantation.
- MRD minimal residual disease
- Ex vivo expanded NK cells of donor origin can be used for the treatment of recurrent malignant disease following allogeneic stem cell transplantation.
- Autologous NK cells can be administered, either prophylactically or therapeutically, to patients undergoing autologous stem cell transplantation for cancer.
- Other ways of using autologous NK cells is for ex vivo purging of malignant cells in the harvest, for treatment of patients with hematological malignancies, and as a cellular therapy for solid tumors.
- Another embodiment of the invention is therefore a method of curative or prophylactic treatment, wherein expanded, activated and cytotoxic NK cells with the phenotype CD56 + CD3 ⁇ , as described above, are administered to patients with a malignant disease, or to a patient with a malignant disease following allogeneic stem cell transplantation, or patients undergoing autologous stem cell transplantation for cancer, or patients with hematological malignancies, or patients with solid tumors, in a pharmaceutically effective dose.
- a patient can also be treated with the inventive method in order to prevent recurrence of a malignant disease.
- a composition comprising the NK cells is administered to patients with a malignant disease or patients undergoing autologous stem cell transplantation for cancer, or to a patient with a malignant disease following allogeneic stem cell transplantation or patients with hematological malignancies, or patients with solid tumors, in a pharmaceutically effective dose.
- the composition according to the invention can also be administered to a patient in order to prevent recurrence of a malignant disease.
- malignancies/tumors that can be treated with the inventive method are outlined above.
- a sample (e.g from peripheral blood, bone marrow, or cord) is taken from a patent afflicted with a malignant disease.
- the patient has been treated with conventional cancer therapies but the treatment has been unsuccessful or the malignancy has recurred.
- the method can also be a prophylactic treatment, for example, to prevent recurrence of a malignant disease.
- the cells e.g. PBMCs
- they are purified and separated according to methods well known for the skilled person.
- the cells are thereafter ex vivo expanded as outlined above and in the “Examples”. Subsequently, the expanded cells are administered to the patient.
- Samples can, for example, be taken from blood, bone marrow and or urine for follow-up of the treatment at regular time intervals.
- the NK cells are preferably are ex vivo expanded for at least about 5 days, preferably not less than about 10 days, more preferably not less than about 15 days and most preferably not less than about 20 days before administration to the patient.
- the NK cells have been expanded at least about 100 fold, preferably at least about 200 fold, and more preferably at least about 400 fold, preferably at least about 600 fold, more preferably at least about 1000 fold and even more preferably at least about 1500 fold compared to day 0 of expansion, before administration to a patient.
- the inventive method can be performed once or repeated several times.
- the NK cells according to the invention are administered to the patient about 1-10 times, preferably about 1-7 times, more preferably about 1-5 times and most preferably about 1-3 times.
- the administration route can be any suitable way of administration well known to the skilled person for example, but not limited to; intravenous, intraperitoneal and intratumoral administration.
- the dosage can be the same in all administrations or for example high in the first administration(s) and than lower in subsequent administrations.
- NK cells of the invention may further increase the effect of administered cells.
- immunomodulatory drugs such as, but not limited to, thalidomide or proteosome inhibitors such as, but not limited to, bortezomib, may further increase the effect of administered cells.
- the features of the ex vivo expanded and activated NK cells to be used in the method of treatment are as described above for the NK cells according to the invention.
- FIG. 1 shows expansion dynamics of blood and bone marrow samples obtained from seven multiple myeloma patients and cultured for 20 days under identical conditions.
- Bulk cells in culture expanded to a total of 511 fold (A).
- Initial OKT-3 treatment lead to an increased percentage of T cells in the culture during the first five days of culture followed by a decrease after withdrawal of OKT-3 (B). The subsequent increase continued until finally NK cells dominated in the culture (C). Results are shown as means +SD.
- FIG. 2 shows changes in the receptor expression patterns of NK cells following expansion and activation.
- Representative data (Patient 5 ) showing comparative phenotyping of day 0 (grey) and day 20 (white) cells (A).
- FIG. 3 shows the results from the cell mediated cytotoxicity assays.
- NK cell cytotoxicity against K562 cell line was measured by the standard chromium release assay and flow cytometry based cytotoxicity assay (A).
- the flow cytometry based cytotoxicity assay demonstrates an increased cytotoxicity of expanded NK cells (day 20) against autologous MM cells compared to freshly isolated NK cells (B). Expansion and activation of the cells did not affect the cytotoxicity against autologous normal BM cells (B). Representative data (Patient 5 ) is shown to demonstrate the analysis procedure (C).
- FIG. 5 shows CD107a mAb based degranulation assay against primary MM cells.
- Representative data (Patient 5 ) demonstrating the expression of CD107a on NK cells after contact with the NK sensitive K562 cell line and autologous MM cells (A).
- Comparison of CD107a expression on day 0, 5 and 20 NK cells upon contact with 519 autologous MM cells (B). The results are shown as percent CD107a cells +SD (N 3).
- PBMCs peripheral blood mononuclear cells
- MM Multiple Myeloma
- BM samples from seven newly diagnosed patients at different stages of MM were included in the study. The patients were followed at the Department of Hematology, Karolinska University Hospital Huddinge, Sweden. The study was approved by the local research ethics committee. Informed consents were obtained from all patients. Patients' characteristics at the time of blood and BM sampling for the study are given in Table 1.
- PBMCs as well as BM mononuclear cells were isolated by gradient centrifugation, using Lymphoprep (Axis-Shield, Oslo, Norway). PBMCs and BMMCs were washed twice with phosphate-buffered saline (PBS) (Gibco, Grand Island, N.Y., USA), and cell viability was assessed by Trypan blue exclusion. To avoid inter-experimental variability, PBMCs and BMMCs were directly frozen in human serum albumin (Baxter) containing 6% DMSO (Wak-chemie medical, Germany) for subsequent phenotyping and cytotoxicity experiments.
- PBS phosphate-buffered saline
- PBMCs and BMMCs were directly frozen in human serum albumin (Baxter) containing 6% DMSO (Wak-chemie medical, Germany) for subsequent phenotyping and cytotoxicity experiments.
- PBMCs were initially thawed and cultured in T25 flasks (TPP, Trasadingen, Switzerland) at a concentration of 0.5 ⁇ 10 6 cells/ml in CellGro SCGM serum-free medium (CellGenix, Freiburg, Germany) with the addition of 5% human serum (Biowhittaker-Cambrex, Md., USA) and 500 U/ml rhlL-2 (Proleukin®, Chiron Corporation, Emeryville, Calif., USA).
- the medium was further supplemented with anti-CD3 antibody (Orthoclone OKT-3, Ortho Biotech Inc., Raritan, N.J., USA) to a final concentration of 10 ng/ml.
- anti-CD3 antibody Orthoclone OKT-3, Ortho Biotech Inc., Raritan, N.J., USA
- the OKT-3-containing medium was washed out, and fresh medium with IL-2 (500 U/ml) and 5% human serum was added.
- the cultures were then replenished with fresh medium every other day throughout the culture period.
- Total cell numbers were assessed by staining cells with Trypan blue dye on days 0, 5-6, 9-10, 14-15, and 20 of culture. Absolute cell counts were calculated by multiplying the total number of cells with the percentage of these subsets determined by flow cytometry. To prevent contact inhibition of cell growth, the cells were transferred to bigger flasks when necessary. The final products were evaluated for purity, viability and phenotype.
- NK cell expansion approached log-linearity after an initial non-proliferative phase of about five days.
- day 20 the total cell population had expanded on average 511-fold (range: 123-1545) ( FIG. 1A ) and, of these, NK cells had expanded on average 1625-fold (range: 502-2658) ( FIG. 1B ).
- NK cells Due to the relatively greater expansion of NK cells compared to the other cell types, NK cells dominated the culture towards the end of the culture period, reaching on average 66% of the cells by day 20 ( FIG. 1C ).
- the percentage of NK-like T cells did not change significantly during the culture period (day 0: 14%, day 20: 18%), while the percentage of T cells (CD56 ⁇ CD3 + ) declined following withdrawal of OKT3 at day 5, decreasing to an average of 14%.
- This panel included fluorochrome conjugated mAbs against the following surface antigens: CD2 (RPA-2.10), CD3 (UCHT-1), CD4 (SK3), CD7 (M-T701), CD8 (HIT8a), CD14 (MOP9), CD16 (3G8), CD19 (HIB19), CD25 (M-A251), CD27 (M-T271), CD38 (HIT2), CD56 (B159), CD57 (NK-1), CD161 (DX12), CD183 (3D12), CD184 (12G5), CD195 (2D7/CCR5), CD197 (1C6/CXCR3), CD226 (DX11), NKB1 (DX9), LFA-1 (HI111), CD62L (DREG56), CD69 (FN50) and CD138 (MI15) purchased from BD Biosciences, San Jose, Calif., USA; CD48 (MEM102) from Biosource AB, Sweden; CD158B1/B2,j (GL183), CD244 (2B4) (C1.7
- the labeled cells were then washed with PBS and fixed in 4% PFA prior to data acquisition.
- Cells were analyzed by nine-color flow cytometry (CyAnTM ADP LX, Dako A/S, Glostrup, Denmark) calibrated with CompBeadsTM and appropriate isotype controls (BD Biosciences).
- the acquired data were analyzed with Dako Cytomation Summit software versions 4.2 and 4.3 (Dako A/S) and FlowJo software version 7.2 for PC (Tree Star Inc., Ashland, Oreg., USA) setting appropriate SSC/FSC gates around the lymphocyte population and using LIVE/DEAD Fixable Red Dead Cell Stain negative cells.
- NK cells were gated as the CD56 + CD3 ⁇ population.
- NK-like T cells and T cells were gated as CD3+CD56+ and CD3+CD56 ⁇ populations respectively.
- MM cells were gated as CD38+CD138+. In each sample a minimum of 105 cells was analyzed.
- MFI mean fluorescence intensity
- FIG. 2A To characterize the final expansion product with respect to the starting material, a detailed flow cytometric analysis was undertaken (representative data of one patient is shown in FIG. 2A ). For each receptor analyzed, MFI values were calculated in samples from day 0 and day 20 cultures and used their ratio (MFlday20/MFlday0) as an indicator of the change.
- FIG. 2B illustrates the MFI ratios of all patients for all receptors analyzed as well as the median values. Briefly, in the final product, the inventors observed a significantly upregulated expression of the following activating receptors: 2B4, CD8, CD16, CD27, CD226, NKG2C, NKG2D, NKp30, NKp44 and NKp46.
- the inhibitory receptors KIR2DL3 and LIR-1 were also upregulated.
- the chemokine receptor CCR7 was significantly down-regulated whereas CXCR3 was markedly upregulated. No significant changes in the expression levels of CD2, CD7, CD57, CD62L, CD69, CD161, LFA-1, GL183, KIR2DL1, NKB1, NKG2A, CCR5 or CXCR4 were observed.
- K562 target cells were labelled with 100 ⁇ Ci of 51Cr for one hour at 37° C., washed twice with PBS, and resuspended in 1 ml of RPMI medium.
- a total of 3 ⁇ 104 target cells in 100 ⁇ l RPMI medium was placed in triplicates into V-bottom 96-well plates and incubated for 4 hours with 100 ⁇ l of effector cells at appropriate concentrations to obtain effector:target ratios from 1:3 to 10:1.
- Aliquots of supernatants were then counted using a Packard Cobra Auto-Gamma 5000 Series Counting System (Meriden, Conn., USA).
- day 5 cells from three patients were also tested for cytotoxicity against K-562 cell line and primary autologous myeloma cells.
- effector cells were preincubated at 4° C. for 30 minutes with 10 ⁇ g/ml of isotype controls or the mAbs against the following receptors: 2B4 (C1.7)19, CD226 (DX11)20, NKG2C (134522), NKG2D (1D11)21, NKp30 (Z25)22, NKp44 (Z231)22, NKp46 (BAB281)22, and CD27 (1A4)23.
- the present NK cells would only be useful if they are able to target autologous MM cells.
- the inventors thus assessed cytotoxicity against autologous MM cells by a flow cytometry based assay.
- day 20 marked cytotoxic activity of NK cells against autologous MM cells was observed whereas both day 0 and day 5 cells showed no or only low levels of cytotoxicity ( FIG. 3B ).
- FIG. 3 c representsative data of one patient is shown in FIG. 3 c ).
- no significant cytotoxicity against non-MM (CD138-) cells was observed.
- Ex vivo expanded NK cells show increased cytotoxicity against autologous MM cells.
- NK cells were coincubated with target cells at a ratio of 1:1 in a final volume of 200 ⁇ l in round-bottomed 96-well plates at 37° C. and 5% CO 2 for 6 h. Fluorochrome-conjugated anti-CD107a mAb or the corresponding IgG1 isotype control was added at the initiation of the assay. After 1 h of coincubation, Monensin (GolgiStop, Becton Dickinson) was added at a 1:100 dilution. Surface staining was done by incubating cells with anti-CD3 and anti-CD56 mAbs for 30 mins on ice. The cells were then washed, resuspended in PBS and immediately analyzed by flow cytometry.
- MM cells are considered to be resistant to lysis by resting and short term activated autologous NK cells. Similar to the immune system defects mentioned above, this resistance has been explained by NK cell dysfunctions in MM patients including impaired NK cytotoxicity and increased levels of soluble IL-2 receptors as well as decreased expression of a number of activating receptors compared to healthy controls. The results indicate that expansion and/or long term activation of NK cells may reverse this potential dysfunction, since it was paralleled by induction of surface expression of CD107a and cytotoxicity of autologous MM.
- expanded NK cells are the major effector compartment exerting autologous anti-MM activity under the present experimental conditions.
- the inventors also phenotyped the expanded NK cells. This allowed a comparison of day 0 and day 20 NK cells. Since a balance of activating and inhibitory signals regulates NK cell function, optimal NK cell effector function is expected to occur in situations where the expression of activating NK cell receptors is adequate and not suppressed by inhibitory signals.
- CD226 which is a tumor surveillance receptor on NK cells, and a potent inducer of cytotoxicity against many tumor cell lines of hematopoetic and non-hematopoetic origin, could also contribute to the increase in cytotoxicity.
- CD27 NK cells are tightly regulated by inhibitory receptors whereas CD27 high NK cell subset is more cytotoxic.
- the upregulation of CD27 during expansion may also contribute to elevated levels of cytotoxicity.
- NK cell based immunotherapy involve infusion of resting and short-term IL-2 activated NK cells to patients with malignancies. These trials have shown that adoptively transferred NK cells are well tolerated.
- the present results shows that the present ex vivo expanded autologous NK cells have a promising anti-MM potential compared to resting or short-term activated NK cells.
- the high levels of NK cell expansion using cGMP quality components is of particular importance in relation to reaching an appropriate infusion dose in settings of immunotherapy.
- NK cells A concern for the use of activated NK cells, especially in the allogeneic settings, is that they could cause a tissue damaging reaction.
- the present data shows that the recognition of autologous MM cells by ex vivo expanded NK cells involve a certain degree of specificity. The inventors demonstrated that day 20 NK cells lysed MM cells but spared non-MM cells from the same patient.
Abstract
The present invention relates to expanded NK cells. The NK cells have been expanded ex vivo, are activated and have a cytotoxic phenotype. The cytotoxicity against malignant cells is markedly increased compared to non-expanded NK cells. The invention also relates to a method of treatment.
Description
- The present invention relates to expanded natural killer (NK) cells being cytotoxic against malignant cells and a method of treatment of malignant disease.
- NK cells are cytotoxic lymphocytes that lyse certain tumor and virus infected cells without any prior stimulation or immunization. NK cells are also potent producers of various cytokines, e.g. IFN-γ, TNF-α, GM-CSF and IL-3. Therefore, NK cells are also believed to function as regulatory cells in the immune system, influencing other cells and responses.
- In humans, NK cells are broadly defined as CD56+CD3− lymphocytes. The cytotoxic activity of NK cells is tightly controlled by a balance between the activating and inhibitory signals from receptors on the cell surface. A main group of receptors that inhibits NK cell activation are the inhibitory killer immunoglobulin-like receptors (KIRs). Upon recognition of self MHC class I molecules on the target cells, these receptors deliver an inhibitory signal that stops the activating signalling cascade, keeping cells with normal MHC class I expression from NK cell lysis. Activating receptors include the natural cytotoxicity receptors (NCR) and NKG2D that push the balance towards cytolytic action through engagement with different ligands on the target cell surface. Thus, NK cell recognition of target cells is tightly regulated by processes involving the integration of signals delivered from multiple activating and inhibitory receptors.
- Several strategies have been used to enhance NK cell responses to tumors. Cytokines are used in the treatment of some human cancers and NK cell differentiation and activation is affected by cytokines such as interleukins (e.g. IL-2, IL-12. IL-15, IL-18 and IL-21). The effect of IL-2 administration on activation and expansion of NK cells in cancer patients have been assessed in several trials with mixed outcomes depending on type of tumor and the conditions used for IL-2 administration. One example of cellular therapy is the NK cell-mediated killing of leukaemia cells which is based on NK cell alloreactivity.
- Multiple myeloma (MM) is a plasma cell neoplasm characterized by the clonal proliferation of plasma cells in the bone marrow (BM). The malignant cells are associated with the synthesis of monoclonal immunoglobulin and a high incidence of osteolytic bone lesions. The disease accounts for about 2% of all cancer deaths and nearly 20% of deaths caused by hematological malignancies. Although allogeneic stem cell transplantation occasionally cures these patients and drugs like thalidomide, lenalidomide and bortezomib have improved outcome, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) still appears to be the best treatment for patients up to 65-70 years of age. However the great majority of patients with MM are incurable due to the persistence of minimal residual disease. Thus, novel methods for complementing or improving current treatments are needed.
- In order to use NK cells in adoptive immunotherapeutic strategies, the availability of functionally active NK cells on a clinical scale is crucial. Clinical trials that have been performed using autologous NK cells were hampered by the fact that the cell dose was inadaptable to the demands of clinical trials. Therefore, the development of protocols for large-scale generation of NK cells is important to evaluate the potential of NK cell-based therapeutic protocols. Examples of reports that deal with ways of expanding and culturing human NK-cells are U.S. Ser. No. 10/242,788 and WO 2006/052534.
- Human ex vivo expanded NK cells would be favorable candidates for immunotherapeutic approaches against malignant disease if they could target tumor cells.
- One aim of the invention is to provide expanded and active CD56+CD3− NK cells.
- Another aim of the invention is to provide expanded CD56+CD3− NK cells that are cytotoxic against cells of malignant disease.
- Yet another aim is to provide a method of treatment of a malignant disease.
- The present invention relates to ex vivo expanded natural killer (NK cells) that can be used for immunotherapy of tumor cells, the NK cells showing no significant cytotoxicity against normal cells. The NK cells according to the invention are ex vivo expanded and active cells having the phenotype CD56+CD3−. This phenotype is specifically toxic against tumor cells. Upregulation of at least one activating receptor contributes to the cytotoxic activity of the expanded NK cells. In one embodiment the invention relates to a composition comprising the NK cells according to the invention.
- In another embodiment the present invention relates to a method of treatment of a malignant disease wherein NK cells according to the invention or a composition according to the invention are/is administered to a patient with a malignant disease, or a patient undergoing autologous stem cell transplantation for cancer, or a patient with a malignant disease following allogeneic stem cell transplantation, or a patient with haematological malignancies, or a patient with solid tumors, in a pharmaceutically effective dose.
- Before the present invention is described, it is to be understood that the terminology employed herein is used for the purpose of describing particular embodiments only and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims and equivalents thereof.
- It must be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
- Also, the term “about” is used to indicate a deviation of +/−2% of the given value, preferably +/−5%, and most preferably +/−10% of the numeric values, where applicable.
- Given their strong cytolytic activity and the potential for auto-reactivity, natural killer (NK) cell activity is tightly regulated. In order to kill cells with a missing or abnormal MHC class I expression the NK cells need to be activated. NK cells must receive an activating signal which can come in a variety of forms, the most important of which are cytokines, Fc receptors, activating and inhibitory receptors. In the content of the present invention the term “activated NK cells” refers to NK cells that have received an activating signal, thus being capable of killing cells with deficiencies in MHC class I expression.
- In the content of the present invention the term “NK cell expansion” relates to the culturing of NK cells that go through a series of cell division and thus expand in number of cells present in the culture. The term “expanded NK cells” relates to NK cells obtained through NK cell expansion. More specifically, in one embodiment the term “expanded NK cells” relates to a polyclonal group of chronically activated CD56+CD3− cells, expanded in a specific cGMP grade environment and cGMP grade medium.
- In the content of the present invention the term “upregulation of receptor” relates to the increase in receptor density per cell.
- In the content of the present invention cells that have a “cytotoxic phenotype” relates to cells that are toxic, i.e. they induce the death of other cells such as, but not limited to, tumor cells, infected cells or cells that are otherwise damaged or dysfunctional. Cytotoxic cells of the present invention are mainly toxic to tumor cells. The cytotoxicity of NK cells towards other cells can easily be measured, for example, by traditional cell counting before and after exposure to the NK cells according to the invention. Such methods are well known to a person skilled in the art. Examples of suitable methods are, but not limited to, fluorescent cell counting assay, immunofluorescent cell counting assay, cell viability assay, and flow cytometry-based cytotoxicity assay.
- In the context of the present invention the term “effector cell” relates to a cell that performs a specific function in response to a stimulus such as cells in the immune system. In one embodiment effector cells are a type of lymphocytes that are actively engaged in secreting antibodies. Non-limiting examples of effector cells are NK cells, T cells and NK-like T cells
- Ex vivo expansion and reinfusion of natural killer (NK) cells to patients afflicted with a malignant disease offers a new potentially interesting therapeutic approach to combat such a disease. A prerequisite for this is the possibility to expand and use NK cells that meet the demands of clinical trials. The present inventors have surprisingly shown that ex vivo expanded NK cells can be used for immunotherapy of tumor cells that often express varying levels of MHC class I molecules, the NK cells showing no significant cytotoxicity against normal cells.
- Accordingly, the present invention relates to ex vivo expanded and activated natural killer cells having the phenotype CD56+CD3−. The NK cells according to the invention are expanded, active and have a phenotype cytotoxic against tumor cells, preferably autologous tumor cells. The NK cells can be obtained from any conventional source and are preferably derived from peripheral blood, bone marrow, cord blood, cell lines or cytokine stimulated peripheral blood. NK cells can, for example; be expanded from a sample of peripheral blood mononuclear cells (PBMCs). PBMCs are a mixture of monocytes and lymphocytes; blood leucocytes from which granulocytes have been separated and removed. The culture conditions are outlined below in “Experimentals”. According to the present invention the NK cells should be expanded for at least about 5 days, preferably not less than about 10 days, more preferably not less than about 15 days and most preferably not less than about 20 days. Already after 5 days the NK cells can show anti-tumor activity.
- Furthermore, in one embodiment of the invention the NK cells according to the invention should be expanded at least about 100 fold, preferably at least about 200 fold, more preferably at least about 400 fold, more preferably at least about 600 fold, more preferably at least about 1000 fold and even more preferably at least about 1500 fold.
- The activating pathway of NK cells also includes a series of different receptors. Activating receptors do not directly signal through their cytoplasmic tail, but instead associate non-covalently with other molecules containing ITAMs (immunoreceptor tyrosine-based activation motifs), that serve as the signal transducing proteins. Thus, according to one embodiment of the invention the ex vivo expanded and activated NK cells have an upregulated expression of at least one activating receptor. Non-limiting examples of activating receptors are: CD16 (FcγRIII), CD25 (IL-2Rα), CD27, CD28, CD69, CD94, CD122 (IL-2Rβ), CD161, CD226 (DNAM-1), 2B4 (CD244), CD314 (NKG2D), KIR2S, KIR3S, NCRs (natural cytotoxicity receptors) such as NKp30, NKp44, and NKp46, CD85H (ILT-1) and IFN-α/βR. Preferably said at least one activating receptor is selected from the group consisting of 2B4, CD8, CD16, CD 27, CD226, NKG2D, NKp30, NKp44 and NKp46. In one embodiment of the present invention the at least one activating receptor is 2B4 or CD226.
- The NK cells according to the present invention exhibit higher degranulation activity compared to non-expanded NK cells. The degranulation activity can be estimated through the determination of the CD107a expression. CD107a surface expression correlates closely with degranulation and release of cytotoxic granules. Degranulation as measured by CD107a expression correlates to cytotoxic activity of an effector cell, such as an NK cell. The method of determining degranulation activity through the determination of CD107a expression is well known to a person skilled in the art. See, for example, Alter G, Malenfant J M, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294:15-22.
- The change in receptor expression can be calculated by mean fluorescence intensity (MFI) ratios:
-
MFIdayX/MFIday0 - where x is the number of days of expansion of the NK cell.
- When the MFI for day X samples is higher than for
day 0, the MFI ratio will be higher than 1, which indicates the relative extent of upregulation in that receptor. Thus, a MFI ratio of e.g. 1.5 would mean a 50% of upregulation of a specific receptor. The calculation of MFI ratios is well known to persons skilled in the art. - According to one embodiment of the present invention the at least one activating receptor is upregulated by at least about 50%, preferably at least about 75, more preferably at least about 100% and most preferably at least about 200%.
- According to another embodiment of the invention the NK cells have a down-regulated expression of at least one receptor, such as an inhibitory receptor or a chemokine receptor (e.g. CCR7). Non-limiting examples of inhibiting receptors are inhibitory killer immunoglobulin-like receptors (KIRs). Further non-limiting examples of inhibiting receptors are GL183, KIR2DL1, Lir-1, NKB1, and NKG2A. It is possible that none inhibitory receptor can be downregulated in some patients, one inhibitory receptor downregulated in some patients and more than one in some patients. Thus, in one embodiment of the invention the NK cells according to the invention can have an upregulated expression of at least one activating receptor and a down-regulated expression of at lest one receptor. In another embodiment the NK cells according to the invention can have an upregulated expression of at least one activating receptor and a downregulated expression of at lest one inhibitory receptor.
- According to another embodiment of the present invention the expanded and activated NK cells have at least about 100% increased cytotoxicity compared to non-ex vivo expanded NK cells. Preferably at least about 150%, more preferably at least about 200% and most preferably at least about 400% increased cytotoxicity compared to non-expanded NK cells. Non expanded NK cells relates to freshly isolated NK cells and short-term activated NK cells. In the context of this invention the expression “short term activated” means NK cells that have been expanded over night only.
- The increased cytotoxicity of the expanded and activated NK cells can also be an effect mediated by an upregulation of a combination of receptors. Thus, in yet another embodiment the present invention relates to expanded and activated NK cells having an upregulated expression of more than one receptor. Thus, recognition of the target cell by NK cells can involve a combination of receptors that synergistically deliver activating signals.
- Another embodiment of the present invention relates to a composition comprising the expanded and active NK cells as described above. In addition to the NK cells, a composition according to the invention may also contain any suitable physiological buffer, such as, but not limited to, phosphate buffered saline. Suitable physiological buffers are well known to the skilled person. Other substances, such as, but not limited to cytokines such as IL-2 and its derivatives, immunomodulatory drugs and proteosome inhibitors, that increase the effect of the administered cells can also be added to the composition or administered separately. In one embodiment the composition also contains lower levels of other cells. Non-expanded PBMCs usually contain a mixture of different cells, for example, NK cells (CD56+CD3−), NK-like T cells (CD56+CD3+) and T cells (CD56−CD3+). After expansion NK cells are the dominating cell type in the culture but also other cell types can be present in the expanded culture.
- The NK cells according to the invention can also be administered or used in combination with other cancer therapies, such as, but not limited to, surgery, radiation and cytotoxic drugs.
- Several experimental studies have shown that NK cells can eliminate cancer cells. The results of the study underlying the present invention suggest that ex vivo expanded and activated cells have a promising anti-tumor potential compared to resting NK cells. Thus, the present invention also relates to NK cells being cytotoxic against tumor cells, said tumor cells preferably being autologous tumor cells. Autologous tumor cells refer to cells that are reimplated in the same individual as they came from, i.e. the donor and the recipient are the same person. Allogeneic tumor cells, on the other hand, refers to cells taken from different individuals of the same species, i.e. genetically non-identical individuals. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical.
- The NK cells according to the present invention are cytotoxic against tumor cells, said tumor cells being selected from, but not limited to, the group consisting of haematological tumors or malignancies and solid tumors or malignancies. Haematological tumors or malignancies include types of cancer that affects the blood, the bone marrow and the lymph nodes. In particular the NK cell according to the invention is cytotoxic against cells of lymphoma (e.g. Hodgkin's disease and non-Hodgkin's lymphoma), multiple myeloma (MM), and leukaemia (e.g. acute lympoblastic leukemia, acute myelogeneous leukaemia, chronic myelogeneous leukaemia, chronic lymphocytic leukaemia, hairy cell leukaemia). Examples of solid tumors are, but not limited to, hepatocellular tumors, gastrointestinal tumors (such as colon tumors), ovarian tumors, renal tumors, lung tumors and pancreatic tumors. In one particular embodiment of the present invention the NK cells are cytotoxic against multiple myeloma cells.
- Since large numbers of activated NK cells now can be produced and used in the setting of adoptive immunotherapy, the present invention also relates to a method of treatment. In leukemia patients autologous ex vivo expanded and activated NK cells might be helpful for treatment of minimal residual disease (MRD) after autologous stem cell transplantation. According to the invention it would be advantageous to administer autologous ex vivo cultured NK cells, either prophylactically or therapeutically, to patients undergoing autologous hematopoietic stem cell transplantation for diseases such as multiple myeloma which have in general a poor prognosis with high incidence of progressive disease post transplant. Ex vivo expanded NK cells of donor origin can be used for the treatment of recurrent malignant disease following allogeneic stem cell transplantation. Autologous NK cells can be administered, either prophylactically or therapeutically, to patients undergoing autologous stem cell transplantation for cancer. Other ways of using autologous NK cells is for ex vivo purging of malignant cells in the harvest, for treatment of patients with hematological malignancies, and as a cellular therapy for solid tumors.
- Another embodiment of the invention is therefore a method of curative or prophylactic treatment, wherein expanded, activated and cytotoxic NK cells with the phenotype CD56+CD3−, as described above, are administered to patients with a malignant disease, or to a patient with a malignant disease following allogeneic stem cell transplantation, or patients undergoing autologous stem cell transplantation for cancer, or patients with hematological malignancies, or patients with solid tumors, in a pharmaceutically effective dose. A patient can also be treated with the inventive method in order to prevent recurrence of a malignant disease.
- In another embodiment of the inventive method a composition comprising the NK cells is administered to patients with a malignant disease or patients undergoing autologous stem cell transplantation for cancer, or to a patient with a malignant disease following allogeneic stem cell transplantation or patients with hematological malignancies, or patients with solid tumors, in a pharmaceutically effective dose. The composition according to the invention can also be administered to a patient in order to prevent recurrence of a malignant disease.
- Examples of malignancies/tumors that can be treated with the inventive method are outlined above.
- In the inventive method a sample (e.g from peripheral blood, bone marrow, or cord) is taken from a patent afflicted with a malignant disease. In one embodiment the patient has been treated with conventional cancer therapies but the treatment has been unsuccessful or the malignancy has recurred. The method can also be a prophylactic treatment, for example, to prevent recurrence of a malignant disease. Before culturing the cells (e.g. PBMCs), they are purified and separated according to methods well known for the skilled person. The cells are thereafter ex vivo expanded as outlined above and in the “Examples”. Subsequently, the expanded cells are administered to the patient. The patient is thereafter carefully followed-up in order to determine if the patient has responded well to the treatment and to determine if the treatment is to be repeated. Samples can, for example, be taken from blood, bone marrow and or urine for follow-up of the treatment at regular time intervals.
- In the inventive method the NK cells are preferably are ex vivo expanded for at least about 5 days, preferably not less than about 10 days, more preferably not less than about 15 days and most preferably not less than about 20 days before administration to the patient.
- In another embodiment the NK cells have been expanded at least about 100 fold, preferably at least about 200 fold, and more preferably at least about 400 fold, preferably at least about 600 fold, more preferably at least about 1000 fold and even more preferably at least about 1500 fold compared to
day 0 of expansion, before administration to a patient. - The inventive method can be performed once or repeated several times. In one embodiment the NK cells according to the invention are administered to the patient about 1-10 times, preferably about 1-7 times, more preferably about 1-5 times and most preferably about 1-3 times. The administration route can be any suitable way of administration well known to the skilled person for example, but not limited to; intravenous, intraperitoneal and intratumoral administration. The dosage can be the same in all administrations or for example high in the first administration(s) and than lower in subsequent administrations.
- Administration, alone or in combination with the NK cells of the invention, of subcutaneous IL-2 or its derivatives as well as immunomodulatory drugs such as, but not limited to, thalidomide or proteosome inhibitors such as, but not limited to, bortezomib, may further increase the effect of administered cells.
- The features of the ex vivo expanded and activated NK cells to be used in the method of treatment are as described above for the NK cells according to the invention.
- The invention is further described in the description, examples and claims with reference to the attached figures in which:
-
FIG. 1 shows expansion dynamics of blood and bone marrow samples obtained from seven multiple myeloma patients and cultured for 20 days under identical conditions. Bulk cells in culture expanded to a total of 511 fold (A). Initial OKT-3 treatment lead to an increased percentage of T cells in the culture during the first five days of culture followed by a decrease after withdrawal of OKT-3 (B). The subsequent increase continued until finally NK cells dominated in the culture (C). Results are shown as means +SD. -
FIG. 2 shows changes in the receptor expression patterns of NK cells following expansion and activation. Representative data (Patient 5) showing comparative phenotyping of day 0 (grey) and day 20 (white) cells (A). Each patient's MFI ratios (·) ofday 20 today 0 as well as the medians (−) of seven patients were plotted for each receptor (B). The dashed line shows MFI ratios=1 which indicates unaltered receptor expression during the expansion period. Values above the line (MFI ratio>1) indicate upregulation and below (MFI ratio<1) denote downregulation. -
FIG. 3 shows the results from the cell mediated cytotoxicity assays. NK cell cytotoxicity against K562 cell line was measured by the standard chromium release assay and flow cytometry based cytotoxicity assay (A). The flow cytometry based cytotoxicity assay demonstrates an increased cytotoxicity of expanded NK cells (day 20) against autologous MM cells compared to freshly isolated NK cells (B). Expansion and activation of the cells did not affect the cytotoxicity against autologous normal BM cells (B). Representative data (Patient 5) is shown to demonstrate the analysis procedure (C). -
FIG. 4 shows blocking of activating receptors on NK cells. The results are shown as mean 522 inhibition+SD (N=3). -
FIG. 5 shows CD107a mAb based degranulation assay against primary MM cells. Representative data (Patient 5) demonstrating the expression of CD107a on NK cells after contact with the NK sensitive K562 cell line and autologous MM cells (A). Comparison of CD107a expression onday - The invention will now be further described in the experiments outlined below wherein efficient ex vivo NK cell expansion from PBMCs (peripheral blood mononuclear cells) of Multiple Myeloma (MM)+patients using clinical grade components is demonstrated. Furthermore, the ability of these NK cells to kill autologous tumor cells is shown. These data suggest the possibility of using autologous ex vivo expanded NK cells for immunotherapy of MM.
- Peripheral blood and bone marrow (BM) samples from seven newly diagnosed patients at different stages of MM were included in the study. The patients were followed at the Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden. The study was approved by the local research ethics committee. Informed consents were obtained from all patients. Patients' characteristics at the time of blood and BM sampling for the study are given in Table 1.
-
TABLE1 Patient characteristics at the time of blood and bone marrow sampling for the study. MM Stage Patient* Age Gender (Durie &Salmon) MM Type 1 41 Male IIIB IgG- λ 2 80 Male IB IgG- λ 3 80 Male IIIB Light chain-λ 4 75 Female IIA IgG- λ 5 66 Female IIB IgG-λ 6 53 Female IA IgG-κ 7 64 Male IIB Light chain-κ *All the patients included in this study were diagnosed in the first half of 2006 and had not yet started any treatment regimen at sampling time. - PBMCs as well as BM mononuclear cells (BMMCs) were isolated by gradient centrifugation, using Lymphoprep (Axis-Shield, Oslo, Norway). PBMCs and BMMCs were washed twice with phosphate-buffered saline (PBS) (Gibco, Grand Island, N.Y., USA), and cell viability was assessed by Trypan blue exclusion. To avoid inter-experimental variability, PBMCs and BMMCs were directly frozen in human serum albumin (Baxter) containing 6% DMSO (Wak-chemie medical, Germany) for subsequent phenotyping and cytotoxicity experiments.
- Material & Methods: The culture conditions for the expansion of cytotoxic cells have previously been optimized on PBMCs from healthy individuals (Carlens et al., Hum. Immunol. 2001; 62:1092-1098). Briefly, PBMCs were initially thawed and cultured in T25 flasks (TPP, Trasadingen, Switzerland) at a concentration of 0.5×106 cells/ml in CellGro SCGM serum-free medium (CellGenix, Freiburg, Germany) with the addition of 5% human serum (Biowhittaker-Cambrex, Md., USA) and 500 U/ml rhlL-2 (Proleukin®, Chiron Corporation, Emeryville, Calif., USA). For the first 5 days, the medium was further supplemented with anti-CD3 antibody (Orthoclone OKT-3, Ortho Biotech Inc., Raritan, N.J., USA) to a final concentration of 10 ng/ml. On
day 5 of culture, the OKT-3-containing medium was washed out, and fresh medium with IL-2 (500 U/ml) and 5% human serum was added. The cultures were then replenished with fresh medium every other day throughout the culture period. Total cell numbers were assessed by staining cells with Trypan blue dye ondays 0, 5-6, 9-10, 14-15, and 20 of culture. Absolute cell counts were calculated by multiplying the total number of cells with the percentage of these subsets determined by flow cytometry. To prevent contact inhibition of cell growth, the cells were transferred to bigger flasks when necessary. The final products were evaluated for purity, viability and phenotype. - Results: In order to study whether it is possible to expand NK cells from MM patients using GMP grade components, cultures of PBMCs from seven patients with MM were established. At the start of the culture (day 0), the mean percentage of NK cells (CD56+CD3−) was 11% (range: 7-17%) whereas T cells constituted 57% (range: 36-81%). NK cell expansion approached log-linearity after an initial non-proliferative phase of about five days. By
day 20, the total cell population had expanded on average 511-fold (range: 123-1545) (FIG. 1A ) and, of these, NK cells had expanded on average 1625-fold (range: 502-2658) (FIG. 1B ). Due to the relatively greater expansion of NK cells compared to the other cell types, NK cells dominated the culture towards the end of the culture period, reaching on average 66% of the cells by day 20 (FIG. 1C ). The percentage of NK-like T cells (CD56+CD3+) did not change significantly during the culture period (day 0: 14%, day 20: 18%), while the percentage of T cells (CD56−CD3+) declined following withdrawal of OKT3 atday 5, decreasing to an average of 14%. These results show that NK cells from MM patients can be expanded efficiently ex vivo by using the present 20 day culture approach. - Material & Methods: The cell phenotype and expansion dynamics of subpopulations were analyzed by flow cytometry on
days 0, 5-6, 9-10, 14-15 and 20 of culture using standard procedures with fluorochrome conjugated mAbs against the following surface antigens CD3, CD14, CD38, CD56 and CD138. -
Day 0 andday 20 cells from all patients were subjected to a more detailed immunophenotypic analysis. To avoid inter-acquisition variability, all frozen samples were simultaneously thawed for a detailed phenotypic characterization of CD56+CD3− (NK) cell subset by flow cytometry. This panel included fluorochrome conjugated mAbs against the following surface antigens: CD2 (RPA-2.10), CD3 (UCHT-1), CD4 (SK3), CD7 (M-T701), CD8 (HIT8a), CD14 (MOP9), CD16 (3G8), CD19 (HIB19), CD25 (M-A251), CD27 (M-T271), CD38 (HIT2), CD56 (B159), CD57 (NK-1), CD161 (DX12), CD183 (3D12), CD184 (12G5), CD195 (2D7/CCR5), CD197 (1C6/CXCR3), CD226 (DX11), NKB1 (DX9), LFA-1 (HI111), CD62L (DREG56), CD69 (FN50) and CD138 (MI15) purchased from BD Biosciences, San Jose, Calif., USA; CD48 (MEM102) from Biosource AB, Stockholm, Sweden; CD158B1/B2,j (GL183), CD244 (2B4) (C1.7), NKG2D (ON71), NKp30 (Z25), NKp44 (Z231), NKp46 (BAB281), LIR-1 (HP-F1), Valpha24 (C15), Vbeta11 (C21) from Beckman Coulter Inc., Fullerton Calif., USA; NKG2A (131411), NKG2C (134591), KIR2DL1 (143211), KIR2DL3 (180701) from R&D Systems, Minneapolis, Minn., USA. - All antibody stainings for flow cytometry were done according to the following protocol. Fc receptors were blocked by incubation with 1 μg human IgG per 105 cells for 15 minutes on ice. The cells were then washed once with PBS and incubated with appropriate amounts of antibody at 4° C. for 30 minutes followed by another wash with PBS. For both panels, LIVE/DEAD Fixable Red Dead Cell Stain (Invitrogen, Carlsbad, Calif., USA) was used for dead cell exclusion according to the manufacturer's instructions. Briefly, 1 μl of dye was applied to 1×106 cells resuspended in 1 ml of PBS and incubated on ice for 30 minutes. The labeled cells were then washed with PBS and fixed in 4% PFA prior to data acquisition. Cells were analyzed by nine-color flow cytometry (CyAn™ ADP LX, Dako A/S, Glostrup, Denmark) calibrated with CompBeads™ and appropriate isotype controls (BD Biosciences). The acquired data were analyzed with Dako Cytomation Summit software versions 4.2 and 4.3 (Dako A/S) and FlowJo software version 7.2 for PC (Tree Star Inc., Ashland, Oreg., USA) setting appropriate SSC/FSC gates around the lymphocyte population and using LIVE/DEAD Fixable Red Dead Cell Stain negative cells. From the lymphocyte gate, NK cells were gated as the CD56+CD3− population. NK-like T cells and T cells were gated as CD3+CD56+ and CD3+CD56− populations respectively. MM cells were gated as CD38+CD138+. In each sample a minimum of 105 cells was analyzed.
- For each cell surface receptor analyzed, mean fluorescence intensity (MFI) values were calculated for
day 0 andday 20 samples. To estimate the change in receptor expression, MFI ratios were calculated (MFlday20/MFlday0) for each receptor. When the MFI forday 20 samples was higher than forday 0, the MFI ratio was higher than 1, which indicated the relative extent of up regulation in that receptor. Likewise, an MFI ratio below 1 was interpreted as down regulation in the expression of that receptor. - Results: To characterize the final expansion product with respect to the starting material, a detailed flow cytometric analysis was undertaken (representative data of one patient is shown in
FIG. 2A ). For each receptor analyzed, MFI values were calculated in samples fromday 0 andday 20 cultures and used their ratio (MFlday20/MFlday0) as an indicator of the change.FIG. 2B illustrates the MFI ratios of all patients for all receptors analyzed as well as the median values. Briefly, in the final product, the inventors observed a significantly upregulated expression of the following activating receptors: 2B4, CD8, CD16, CD27, CD226, NKG2C, NKG2D, NKp30, NKp44 and NKp46. The inhibitory receptors KIR2DL3 and LIR-1 were also upregulated. The chemokine receptor CCR7 was significantly down-regulated whereas CXCR3 was markedly upregulated. No significant changes in the expression levels of CD2, CD7, CD57, CD62L, CD69, CD161, LFA-1, GL183, KIR2DL1, NKB1, NKG2A, CCR5 or CXCR4 were observed. - Material & Methods: The cytotoxic capacity of NK cells before and after expansion was evaluated in vitro with a standard 4 hour 51 Cr-release assay against NK-sensitive K562 cells. Because the 51 Crrelease assay is not suitable for primary MM cells 16-18, a flow cytometry based cell mediated cytotoxicity assay was used.
- For the 51 Cr-release assay, K562 target cells were labelled with 100 μCi of 51Cr for one hour at 37° C., washed twice with PBS, and resuspended in 1 ml of RPMI medium. A total of 3×104 target cells in 100 μl RPMI medium was placed in triplicates into V-bottom 96-well plates and incubated for 4 hours with 100 μl of effector cells at appropriate concentrations to obtain effector:target ratios from 1:3 to 10:1. Aliquots of supernatants were then counted using a Packard Cobra Auto-Gamma 5000 Series Counting System (Meriden, Conn., USA). The percentage of specific 51Cr release was calculated according to the formula: percent specific release=[(experimental release−spontaneous release)/(maximum release−spontaneous release)]×100.
- For the flow cytometry based assay, autologous MM cells or K562 controls were labelled with TFL4 reagent of the CytoToxiLux-PLUS kit (Oncolmmunin Inc., Gaithersburg, Md., USA) according to the manufacturer's instructions. 5×104 target cells were placed in tubes together with different amounts of effector cells to obtain effector:target ratios from 1:3 to 10:1 in a final volume of 300 μl RPMI medium and incubated at 37° C. for 4 hours. The cells were then washed once with PBS. Following Fc receptor blockade with IgG (1 μg/105 cells) on ice for 20 minutes to avoid antibody-dependent cellular cytotoxicity, the cells were incubated with appropriate amounts of fluorochrome conjugated mAbs against CD3, CD34, CD38, CD56 and CD138 at 4° C. for 30 minutes. After washing with PBS, the cells were resuspended in 500 μl of PBS containing 5 μg 7-aminoactinomycin D (7-AD; Invitrogen, Carlsbad, Calif., USA) and incubated in the dark for an additional 15 minutes at 4° C. before data acquisition by nine-color flow cytometry. Cytotoxicity was assessed according to the following formula: percent killing =[(experimental death-spontaneous death)/(maximum death-spontaneous death)]×100.
- To compare cytotoxicity of short term activated and expanded cells,
day 5 cells from three patients were also tested for cytotoxicity against K-562 cell line and primary autologous myeloma cells. - For blocking experiments, effector cells were preincubated at 4° C. for 30 minutes with 10 μg/ml of isotype controls or the mAbs against the following receptors: 2B4 (C1.7)19, CD226 (DX11)20, NKG2C (134522), NKG2D (1D11)21, NKp30 (Z25)22, NKp44 (Z231)22, NKp46 (BAB281)22, and CD27 (1A4)23.
- Results: The inventors next investigated the cytotoxic activity of ex vivo expanded NK cells against a standard NK target cell line, K562. Cytotoxicity against K562, measured by a flow cytometry-based cytotoxicity assay and confirmed by a standard 4-hour chromium release assay, was markedly increased by
day 20 NK cells when compared today 0 andday 5 cells (FIG. 3A ). At a 10:1 effector to target cell ratio, 62% of the K562 targets were killed by theday 20 NK cells whereasday 0 andday 5 cells killed only 8% and 29% of K562 targets, respectively, at a similar effector to target ratio. - In an in vivo immunotherapy approach, the present NK cells would only be useful if they are able to target autologous MM cells. The inventors thus assessed cytotoxicity against autologous MM cells by a flow cytometry based assay. At
day 20, marked cytotoxic activity of NK cells against autologous MM cells was observed whereas bothday 0 andday 5 cells showed no or only low levels of cytotoxicity (FIG. 3B ). At a 10:1 effector:target ratio, 61% of autologous MM cells were killed byday 20 cells (representative data of one patient is shown inFIG. 3 c). Notably, no significant cytotoxicity against non-MM (CD138-) cells was observed. Ex vivo expanded NK cells show increased cytotoxicity against autologous MM cells. - To determine the relative contributions of different activating receptors on autologous MM cytotoxicity, effector cells were preincubated with blocking antibodies against several individual activation receptors, or their combinations, and then co-incubated with autologous MM cells. Cytotoxicity was partially inhibited by blocking 2B4 (60% inhibition), CD226 (DNAM-1; 53%), NKG2C (48%), NKG2D (49%), CD27 (50%), NKp30 (57%), NKp44 (55%), and NKp46 (59%) (
FIG. 4 ). This indicates that several activating receptors may contribute to MM cytotoxicity in line with current knowledge of receptor synergy for induction of cytotoxicity. Thus, the cytotoxicity against autologous MM involves target cell interaction with activating NK cell receptors. - Material & Methods: NK cells were coincubated with target cells at a ratio of 1:1 in a final volume of 200 μl in round-bottomed 96-well plates at 37° C. and 5% CO2 for 6 h. Fluorochrome-conjugated anti-CD107a mAb or the corresponding IgG1 isotype control was added at the initiation of the assay. After 1 h of coincubation, Monensin (GolgiStop, Becton Dickinson) was added at a 1:100 dilution. Surface staining was done by incubating cells with anti-CD3 and anti-CD56 mAbs for 30 mins on ice. The cells were then washed, resuspended in PBS and immediately analyzed by flow cytometry.
- Results: In order to better pinpoint the active population within the final expansion product showing cytotoxicity against autologous MM cells, the inventors shifted focus from MM cell lysis to effector cell activation by analyzing the surface expression of CD107a on different subpopulations upon contact with MM cells. CD107a expression correlates closely with degranulation and release of cytotoxic granules. Approximately 30% of
Day 20 NK cells expressed CD107a on the cell surface on contact with K562 cell line. Similar degranulation was observed against autologous MM cells (representative data of one patient is shown inFIG. 5A ). Analysis of expanded cells showed that NK cells were the main degranulating population following challenge with autologous MM cells (FIG. 5B ). Thus, autologous MM cells trigger degranulation of ex vivo expanded NK cells. - Although previous reports suggest that cytokine activation of NK cells may lead to a better recognition of MM cells, MM cells are considered to be resistant to lysis by resting and short term activated autologous NK cells. Similar to the immune system defects mentioned above, this resistance has been explained by NK cell dysfunctions in MM patients including impaired NK cytotoxicity and increased levels of soluble IL-2 receptors as well as decreased expression of a number of activating receptors compared to healthy controls. The results indicate that expansion and/or long term activation of NK cells may reverse this potential dysfunction, since it was paralleled by induction of surface expression of CD107a and cytotoxicity of autologous MM. Based on assessment of induction of degranulation measured by expression of CD107a, it was concluded that expanded NK cells are the major effector compartment exerting autologous anti-MM activity under the present experimental conditions. Within the course of the present studies the inventors also phenotyped the expanded NK cells. This allowed a comparison of
day 0 andday 20 NK cells. Since a balance of activating and inhibitory signals regulates NK cell function, optimal NK cell effector function is expected to occur in situations where the expression of activating NK cell receptors is adequate and not suppressed by inhibitory signals. Reduced 2B4 expression in NK cells from MM patients has been suggested to play a role in the immune escape mechanism of MM expressing its ligand CD4841, however it cannot be excluded that it might be a consequence of interactions between NK and MM cells. The upregulation of 2B4 after ex vivo expansion is likely one factor contributing to the cytotoxicity observed against autologous MM cells. Furthermore, NCRs and NKG2D, which presumably take part in the recognition of MM cells by NK cells, are significantly upregulated, suggesting possible pathways for autologous MM cell killing. The upregulation of CD226 which is a tumor surveillance receptor on NK cells, and a potent inducer of cytotoxicity against many tumor cell lines of hematopoetic and non-hematopoetic origin, could also contribute to the increase in cytotoxicity. Furthermore, it has previously been shown that CD27 NK cells are tightly regulated by inhibitory receptors whereas CD27 high NK cell subset is more cytotoxic. The upregulation of CD27 during expansion may also contribute to elevated levels of cytotoxicity. - Recently published results of clinical trials testing NK cell based immunotherapy involve infusion of resting and short-term IL-2 activated NK cells to patients with malignancies. These trials have shown that adoptively transferred NK cells are well tolerated. The present results shows that the present ex vivo expanded autologous NK cells have a promising anti-MM potential compared to resting or short-term activated NK cells. The high levels of NK cell expansion using cGMP quality components is of particular importance in relation to reaching an appropriate infusion dose in settings of immunotherapy.
- A concern for the use of activated NK cells, especially in the allogeneic settings, is that they could cause a tissue damaging reaction. The present data shows that the recognition of autologous MM cells by ex vivo expanded NK cells involve a certain degree of specificity. The inventors demonstrated that
day 20 NK cells lysed MM cells but spared non-MM cells from the same patient. - Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims that follow. In particular, it is contemplated by the inventor that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims.
Claims (23)
1. Natural killer (NK) cells that are ex vivo expanded and said expanded NK cells are active and have a CD56+CD3− phenotype, said phenotype being cytotoxic against autologous tumor cells.
2. The NK cells according to claim 1 , wherein said NK cells have an upregulated expression of at least one activating receptor.
3. The NK cells according to claim 2 , wherein said activating receptor is upregulated by at least about 50%.
4. The NK cells according to claim 2 , wherein said at least one upregulated activating receptor is a natural cytotoxic receptor (NCR).
5. The NK cells according to claim 2 , wherein said at least one activating receptor is selected from the group consisting of 2B4, CD8, CD16, CD 27, CD226, NKG2D, NKp30, NKp44 and NKp46.
6. The NK cells according to claim 1 , wherein said NK cells have at least about 100% increased cytotoxicity compared to freshly isolated non-expanded NK cells.
7. The NK-cells according to claim 1 , wherein said NK cells have been expanded for at least about 5 days.
8. The NK-cells according to claim 1 , wherein said NK cells have been expanded for at least about 10 days.
9. The NK cells according to claim 1 , wherein said NK cells are cytotoxic against tumor cells, said tumor cells are cells from haematological tumors.
10. The NK cells according to claim 1 , wherein said NK cells are cytotoxic against autologous tumor cells, said tumor cells being selected from the group consisting of cells from multiple myeloma, leukaemia and lymphoma.
11. The NK cells according to claim 1 , wherein said NK cells are cytotoxic against autologous tumor cells, said tumor cells being cells from multiple myeloma.
12. The NK cells according to claim 1 , wherein said NK cells is cytotoxic against autologous tumor cells, said tumor cells being cells from solid tumors.
13. The NK cells according to claim 1 , wherein said NK cells are cytotoxic against autologous tumor cells, said tumor cells being selected from the group consisting of cells from hepatocellular tumors, gastrointestinal tumors, ovarian tumors, renal tumors, lung tumors and pancreatic tumors.
14. The NK cells according to claim 1 , wherein said NK cells exhibit higher degranulation activity compared to non-expanded and activated NK cells as determined by CD107a expression.
15. A composition comprising NK cells according to claim 1 .
16. Method of curative or prophylactic treatment, wherein NK cells according to claim 1 are administered to a patient with a malignant disease following allogeneic stem cell transplantation, or a patient undergoing autologous stem cell transplantation for cancer, or a patient with haematological malignancies, or a patient with solid tumors, in a pharmaceutically effective dose.
17. The method according to claim 16 , wherein the NK cells are administered to a patient to prevent recurrence of a malignant disease.
18. The method according to claim 16 , wherein the NK cells are ex vivo expanded for at least about 5 days prior to administration to the patient.
19. The method according to claim 16 , wherein the NK cells are expanded at least about 100 fold prior to administration to the patient.
20. Method of curative or prophylactic treatment, wherein the composition according to claim 15 is administered to a patient with a malignant disease following allogeneic stem cell transplantation, or a patient undergoing autologous stem cell transplantation for cancer, or a patient with haematological malignancies, or a patient with solid tumors, in a pharmaceutically effective dose.
21. The method according to claim 20 , wherein the composition is administered to a patient to prevent recurrence of a malignant disease.
22. The method according to claim 20 , wherein the NK cells are ex vivo expanded for at least about 5 days prior to administration to the patient.
23. The method according to claim 20 , wherein the NK cells are expanded at least about 100 fold prior to administration to the patient.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/938,123 US20090123442A1 (en) | 2007-11-09 | 2007-11-09 | Expanded nk cells |
US14/830,758 US9585914B2 (en) | 2007-11-09 | 2015-08-20 | Expanded NK cells |
US15/427,176 US20170145383A1 (en) | 2007-11-09 | 2017-02-08 | Expanded nk cells |
US16/847,808 US20200239845A1 (en) | 2007-11-09 | 2020-04-14 | Expanded nk cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/938,123 US20090123442A1 (en) | 2007-11-09 | 2007-11-09 | Expanded nk cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/830,758 Continuation US9585914B2 (en) | 2007-11-09 | 2015-08-20 | Expanded NK cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090123442A1 true US20090123442A1 (en) | 2009-05-14 |
Family
ID=40623914
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/938,123 Abandoned US20090123442A1 (en) | 2007-11-09 | 2007-11-09 | Expanded nk cells |
US14/830,758 Active US9585914B2 (en) | 2007-11-09 | 2015-08-20 | Expanded NK cells |
US15/427,176 Abandoned US20170145383A1 (en) | 2007-11-09 | 2017-02-08 | Expanded nk cells |
US16/847,808 Abandoned US20200239845A1 (en) | 2007-11-09 | 2020-04-14 | Expanded nk cells |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/830,758 Active US9585914B2 (en) | 2007-11-09 | 2015-08-20 | Expanded NK cells |
US15/427,176 Abandoned US20170145383A1 (en) | 2007-11-09 | 2017-02-08 | Expanded nk cells |
US16/847,808 Abandoned US20200239845A1 (en) | 2007-11-09 | 2020-04-14 | Expanded nk cells |
Country Status (1)
Country | Link |
---|---|
US (4) | US20090123442A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011053321A1 (en) * | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
US20120258085A1 (en) * | 2009-03-26 | 2012-10-11 | Evren Alici | Expansion of NK Cells |
EP2687852A1 (en) * | 2012-07-17 | 2014-01-22 | Laboratorios Del. Dr. Esteve, S.A. | Method for diagnosing and treating chronic fatigue syndrome |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
WO2016162827A1 (en) * | 2015-04-09 | 2016-10-13 | Universita' Degli Studi Di Genova | Population of human lymphoid precursors, method for their identification and uses thereof |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
CN109097331A (en) * | 2018-09-25 | 2018-12-28 | 深圳市五零生命科技有限公司 | A kind of NK cell non-serum culture medium |
CN109477838A (en) * | 2016-05-24 | 2019-03-15 | 蔚山大学校产学协力团 | Active inspection method using the NK cell of receptor synergistic activity and the diagnostic method with the disease of the activity relationships of NK cell using it |
KR20190043880A (en) * | 2017-10-19 | 2019-04-29 | 충북대학교 산학협력단 | Composition for promoting differentiation or proliferation of natural killer cell comprising sesamolin |
WO2019231846A1 (en) * | 2018-05-27 | 2019-12-05 | Argos Therapeutics, Inc. | Methods of making natural killer cells and uses thereof |
CN110603320A (en) * | 2017-05-12 | 2019-12-20 | 盖亚生物制药有限公司 | High-activity NK (Natural killer) cell and application thereof |
WO2020018425A1 (en) * | 2018-07-16 | 2020-01-23 | Nantcell, Inc. | Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201 |
CN112399858A (en) * | 2018-04-30 | 2021-02-23 | Xnk制药公司 | Medical use |
EP3922715A4 (en) * | 2019-04-17 | 2022-03-30 | CHA Biotech Co., Ltd. | Natural killer cells exhibiting increased anticancer activity and immunotherapeutic use thereof |
CN116679065A (en) * | 2023-07-31 | 2023-09-01 | 北京大学人民医院 | Application of detection reagent, method for predicting prognosis of multiple myeloma treatment and product |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102081987B1 (en) * | 2016-09-23 | 2020-02-28 | 주식회사 에스엘바이젠 | A novel Natural Killer cell line and use thereof |
US11446329B2 (en) * | 2017-11-01 | 2022-09-20 | Restem Llc | Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
-
2007
- 2007-11-09 US US11/938,123 patent/US20090123442A1/en not_active Abandoned
-
2015
- 2015-08-20 US US14/830,758 patent/US9585914B2/en active Active
-
2017
- 2017-02-08 US US15/427,176 patent/US20170145383A1/en not_active Abandoned
-
2020
- 2020-04-14 US US16/847,808 patent/US20200239845A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068306A1 (en) * | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
Non-Patent Citations (1)
Title |
---|
Fauriat C et al. 2006. Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma. Leukemia 20: 732-733. * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9216200B2 (en) | 2007-09-28 | 2015-12-22 | Anthrogenesis Corporation | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
US20120258085A1 (en) * | 2009-03-26 | 2012-10-11 | Evren Alici | Expansion of NK Cells |
US8877182B2 (en) * | 2009-03-26 | 2014-11-04 | Cellprotect Nordic Pharmaceuticals Ab | Expansion of NK cells |
WO2011053321A1 (en) * | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
US8926964B2 (en) | 2010-07-13 | 2015-01-06 | Anthrogenesis Corporation | Methods of generating natural killer cells |
US9464274B2 (en) | 2010-07-13 | 2016-10-11 | Anthrogenesis Corporation | Methods of generating natural killer cells |
EP2687852A1 (en) * | 2012-07-17 | 2014-01-22 | Laboratorios Del. Dr. Esteve, S.A. | Method for diagnosing and treating chronic fatigue syndrome |
US9763983B2 (en) | 2013-02-05 | 2017-09-19 | Anthrogenesis Corporation | Natural killer cells from placenta |
WO2016162827A1 (en) * | 2015-04-09 | 2016-10-13 | Universita' Degli Studi Di Genova | Population of human lymphoid precursors, method for their identification and uses thereof |
CN109477838A (en) * | 2016-05-24 | 2019-03-15 | 蔚山大学校产学协力团 | Active inspection method using the NK cell of receptor synergistic activity and the diagnostic method with the disease of the activity relationships of NK cell using it |
CN110603320A (en) * | 2017-05-12 | 2019-12-20 | 盖亚生物制药有限公司 | High-activity NK (Natural killer) cell and application thereof |
US11723924B2 (en) | 2017-05-12 | 2023-08-15 | Yoshikazu Yonemitsu | Highly active NK cell and use thereof |
CN107326008A (en) * | 2017-08-09 | 2017-11-07 | 上海莱馥医疗科技有限公司 | A kind of method of high-purity amplifying natural killer cell efficient from peripheral blood |
KR20190043880A (en) * | 2017-10-19 | 2019-04-29 | 충북대학교 산학협력단 | Composition for promoting differentiation or proliferation of natural killer cell comprising sesamolin |
KR101997026B1 (en) | 2017-10-19 | 2019-07-05 | 충북대학교 산학협력단 | Composition for promoting differentiation or proliferation of natural killer cell comprising sesamolin |
CN112399858A (en) * | 2018-04-30 | 2021-02-23 | Xnk制药公司 | Medical use |
WO2019231846A1 (en) * | 2018-05-27 | 2019-12-05 | Argos Therapeutics, Inc. | Methods of making natural killer cells and uses thereof |
WO2020018425A1 (en) * | 2018-07-16 | 2020-01-23 | Nantcell, Inc. | Antibody-dependent cell-mediated toxicity mediated by alt-803 and neo-201 |
CN109097331A (en) * | 2018-09-25 | 2018-12-28 | 深圳市五零生命科技有限公司 | A kind of NK cell non-serum culture medium |
EP3922715A4 (en) * | 2019-04-17 | 2022-03-30 | CHA Biotech Co., Ltd. | Natural killer cells exhibiting increased anticancer activity and immunotherapeutic use thereof |
CN116679065A (en) * | 2023-07-31 | 2023-09-01 | 北京大学人民医院 | Application of detection reagent, method for predicting prognosis of multiple myeloma treatment and product |
Also Published As
Publication number | Publication date |
---|---|
US9585914B2 (en) | 2017-03-07 |
US20170145383A1 (en) | 2017-05-25 |
US20150374754A1 (en) | 2015-12-31 |
US20200239845A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200239845A1 (en) | Expanded nk cells | |
AU2016274633B2 (en) | Methods for the production of TCR gamma delta+ T cells | |
Alici et al. | Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components | |
EP2893003B1 (en) | Selective and controlled expansion of educated nk cells | |
US9114100B2 (en) | Methods of treatment using ex vivo expansion of cord blood T cells | |
Zhang et al. | Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells | |
Veuillen et al. | Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy | |
US20210309969A1 (en) | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using | |
KR20180086204A (en) | Composition for use in immunotherapy | |
CN107847585B (en) | NKT cell subsets for in vivo persistence and therapeutic activity and propagation thereof | |
US11925662B2 (en) | Compositions and methods of enhancing anti-tumor response using hybrid neutrophils | |
Rivoltini et al. | Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype | |
Markus et al. | Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes | |
Yang et al. | Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model | |
US20240117309A1 (en) | Methods for expanding t cell populations | |
Kremer | Fatal Attraction: NK Cell Migration Toward and Activity in Solid Tumors | |
KR20220119080A (en) | Improved Methods for Culturing Therapeutic Tumor-Infiltrating Lymphocytes | |
Wesch et al. | OPEN ACCESS EDITED BY | |
Trefny | Resistance Mechanisms in Cancer Immunotherapy | |
Zhang | The characterization and engineering of human antigen-specific cytotoxic T cells | |
Sarvaria | The differential role of regulatory B cells in cancer and allo-immunity | |
EA043082B1 (en) | METHODS FOR PRODUCING TCR GAMMA DELTA+ T-CELLS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AVARIS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DILBER, SIRAC;ALICI, EVREN;REEL/FRAME:020818/0309;SIGNING DATES FROM 20080225 TO 20080305 |
|
AS | Assignment |
Owner name: CELLPROTECT NORDIC PHARMACEUTICALS AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVARIS AB;REEL/FRAME:029513/0474 Effective date: 20121127 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |